Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) ROCE %: 1.98% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920344 Beijing Tri Prime Gene Pharmaceutical Co Ltd BJSE:920344
77 GF Score
Price ¥18.55
GF Value ¥25.94
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Beijing Tri Prime Gene Pharmaceutical Co ROCE %?

Beijing Tri Prime Gene Pharmaceutical Co BJSE:920344 77 ROCE % is 1.98% as of Mar. 2026. GuruFocus rates BJSE:920344 with a GF Score™ of 77/100 and a GF Value™ of ¥25.94 (Modestly Undervalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beijing Tri Prime Gene Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.98%.

Beijing Tri Prime Gene Pharmaceutical Co  (BJSE:920344) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beijing Tri Prime Gene Pharmaceutical Co ROCE % Related Terms

Beijing Tri Prime Gene Pharmaceutical Co ROCE % Historical Data

* Premium members only.

The historical data trend for Beijing Tri Prime Gene Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Tri Prime Gene Pharmaceutical Co ROCE % Chart

Beijing Tri Prime Gene Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.37 3.70 4.05 3.19 1.42

Beijing Tri Prime Gene Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.31 3.76 -3.49 9.83 1.98
BJSE:920344
77GF Score
Beijing Tri Prime Gene Pharmaceutical Co Ltd BJSE:920344
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Tri Prime Gene Pharmaceutical Co ROCE % Calculation

Beijing Tri Prime Gene Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=15.046/( ( (1229.3 - 155.45) + (1217.807 - 168.108) )/ 2 )
=15.046/( (1073.85+1049.699)/ 2 )
=15.046/1061.7745
=1.42 %

Beijing Tri Prime Gene Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=20.76/( ( (1217.807 - 168.108) + (1208.1 - 157.825) )/ 2 )
=20.76/( ( 1049.699 + 1050.275 )/ 2 )
=20.76/1049.987
=1.98 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 1.98% mean?
Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) has a ROCE % of 1.98% as of Mar. 2026.
Is Beijing Tri Prime Gene Pharmaceutical Co's ROCE % too high?
Beijing Tri Prime Gene Pharmaceutical Co's current ROCE % is 1.98%. Overall, Beijing Tri Prime Gene Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tri Prime Gene Pharmaceutical Co's ROCE % compare to VRTX and REGN?
Beijing Tri Prime Gene Pharmaceutical Co's ROCE % of 1.98% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Beijing Tri Prime Gene Pharmaceutical Co's current ROCE % is 1.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tri Prime Gene Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥25.94, compared to a current price of ¥18.55 — trading 28.5% below its estimated fair value. The current ROCE % is 1.98%. Beijing Tri Prime Gene Pharmaceutical Co's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344), the current ROCE % is 1.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Tri Prime Gene Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥18.55 is trading 28.5% below its estimated GF Value™ of ¥25.94. GuruFocus considers Beijing Tri Prime Gene Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for BJSE:920344:

  • ROCE %: 1.98%
  • GF Value™: ¥25.94 vs. price of ¥18.55 (28.5% below fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the BJSE:920344 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Tri Prime Gene Pharmaceutical Co Business Description

Address No. 20, Jinghong Street, Biomedicine Base, Daxing District, Beijing, CHN, 102600
Beijing Tri Prime Gene Pharmaceutical Co Ltd is mainly engaged in the research, development, production, and sales of medical biotechnology products, including genetic engineering drugs, genetic engineering vaccines, and diagnostic reagents, and is engaged in related technical trade and technical consulting services. Its product line comprises Yundex Spray, Yundex Eye Drops, Yundexol Powder Injection, and Yundexol Water Injection.
77GF Score

Get the complete analysis for BJSE:920344

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥18.55
Price
¥25.94
GF Value